Skip to search formSkip to main contentSkip to account menu

vidofludimus

Known as: 2-(3-fluoro-3'-methoxybiphenyl-4-carbamoyl)cyclopent-1-enecarboxylic acid, 4SC-101 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Background and Objective Vidofludimus is a potent and selective inhibitor of human mitochondrial enzyme dihydroorotate… 
2020
2020
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disorder, and yet with no pharmacological… 
2019
2019
The dihydroorotate dehydrogenase (DHODH) inhibitors leflunomide and teriflunomide are immunomodulatory agents approved to treat… 
Highly Cited
2013
2012
2012
Vidofludimus (Vido) is a novel oral immunomodulatory drug that inhibits dihydro-orotate dehydrogenase and lymphocyte… 
2012
2012
Background 4SC-101 is a novel dihydroorotate dehydrogenase inhibitor and a blocker of interleukin (IL)-17 secretion with… 
Highly Cited
2010
Highly Cited
2010
Background: Dihydroorotate dehydrogenase (DHODH) is a key enzyme involved in pyrimidine biosynthesis. DHODH is a known target for… 
Highly Cited
2010
Highly Cited
2010
Immunosuppressive treatments of systemic lupus (SLE) remain associated with significant toxicities; hence, compounds with better… 
2010
2010
Immunosuppressive treatments of systemic lupus (SLE) remain associated with significant toxicities; hence, compounds with better…